This phase 3 open-label randomized ICTAN trial demonstrated a significant DFS benefit with 12-month or 6-month icotinib compared to observation in patients with completely resected EGFR-mutated stage II–IIIA NSCLC after adjuvant chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.